Maravai LifeSciences Holdings, Inc. (MRVI) company profile
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
About Maravai LifeSciences
Pharmaceutical Preparations, SIC 2834
Maravai LifeSciences Holdings provides products and services that support the development of drug therapies, vaccines, and diagnostics, as well as human disease research. The business operates through two primary segments: TriLink and Cygnus. The TriLink segment supplies modified nucleic acids and associated technologies, including messenger RNA, CleanCap capping reagents, ModTail modifications, oligonucleotides, nucleoside triphosphates, specialty enzymes, and contract synthesis services. The Cygnus segment focuses on biologics safety testing solutions, offering host cell protein detection kits, viral clearance prediction assays, auxiliary reagents, and custom analytical testing. Its client base spans biopharmaceutical corporations, emerging biotechnology enterprises, academic and life science research institutions, and diagnostic organizations.
As of late 2025, the enterprise employs 435 full-time personnel globally. It serves clients across roughly 60 nations outside the United States using direct sales teams and distributor partners. Operational sites supporting manufacturing, analysis, and distribution are situated in San Diego, California; Leland, North Carolina; Sterling, Virginia; and Jupiter, Florida. The provided text does not state a corporate headquarters.
Summary of the business section of Maravai LifeSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Maravai LifeSciences Holdings, Inc.
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle Suite 200 92121
- Phone
- (858) 546-0004
- Website
- maravai.com
- Employees
- 435, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- MRVI
- Exchange
- Nasdaq
- IPO date
- Nov 23, 2020
- Shares outstanding
- 260M, Jul 31, 2026
- Public float
- $300.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1823239
- CUSIP
- 56600D107
- ISIN
- US56600D1072
- FIGI
- BBG00Y1DFV91
- Share class FIGI
- BBG00Y1DFW44
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bernd Brust | Chief Executive Officer, Director | 1,969,520 |
| Rajesh Asarpota | Chief Financial Officer | 412,555 |
| Kurt Oreshack | General Counsel | 335,767 |
| Christine Dolan | See Remarks | 425,318 |
| Peter Michael Leddy | See Remarks | 727,177 |
| Kevin Herde | Chief Financial Officer | 674,636 |
| William E. Martin Iii | Chief Executive Officer | 1,814,643 |
| Rebecca Buzzeo | See Remarks | 310,933 |
| Andrew Burch | See Remarks | 369,183 |
| Gregory T. Lucier | Director | 311,200 |
| Sean Laurence Cunningham | Director | 184,348 |
| R. Andrew Eckert | Director | 412,183 |
| Luke Joseph Marker | Director | 184,348 |
| Susannah Gray | Director | 216,200 |
| Constantine S. Mihas | Director | 184,348 |
| John A. DeFord | Director | 205,478 |
| Murali Prahalad | Director | 154,607 |
| Jessica Hopfield | Director | 199,907 |
| Benjamin James Daverman | Director | 138,055 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Burst | $10.13M | $14.01M | $2.00M | $11 | $131 |
| FY2025 Mr.Martin | $3.85M | -$1.97M | $2.00M | $11 | $131 |
| FY2024 | $6.38M | $5.83M | $2.43M | $18 | $99 |
| FY2023 Mr.Hull | $5.22M | $1.64M | $2.72M | $22 | $100 |
| FY2023 Mr.Martin | $2.30M | -$3.81M | $2.72M | $22 | $100 |
| FY2022 | $5.48M | $3.04M | $2.21M | $48 | $97 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Bernd Brust Chief Executive Officer | $388.86K | – | $7.66M | $1.46M | $425.34K | $195.50K | $10.13M | – |
| William E. Martin III Former Chief Executive Officer | $345.00K | – | $2.60M | – | – | $896.71K | $3.85M | -40% |
| Raj Asarpota Chief Financial Officer | $253.37K | $200.00K | $2.17M | $483.33K | $195.14K | $202.46K | $3.51M | – |
| Kevin Herde Former Chief Financial Officer | $247.77K | – | $1.04M | – | – | $441.55K | $1.73M | -26% |
| Kurt Oreshack Secretary and General Counsel | $455.44K | – | $781.07K | – | $225.32K | $9.15K | $1.47M | – |
| Christine Dolan Executive Vice President and General Manager, Cygnus | $450.97K | – | $650.89K | – | $343.19K | $9.15K | $1.45M | – |
| Peter Leddy Chief Administrative Officer | $372.20K | – | $1.04M | – | $115.84K | $320.35K | $1.85M | -22% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 23, 2020
- Offer price
- $27.00
- Securities offered
- 60,000,000
- Gross proceeds
- $1.62B
- Exchange
- Nasdaq
- First trading day
- Nov 20, 2020
- First-day close
- $29.85+10.6%
- Lock-up ends (est.)
- May 19, 2021
“See “Management—Corporate Governance—Controlled Company Status.” PRICE $27.00 A SHARE Per share Total Initial public offering price $ 27.0000 $ 1,620,000,000 Underwriting discounts and commissions (1) $ 1.4850 $ 89,100,000 Proceeds, before expenses, to Maravai LifeSciences Holdings, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 435 full-time employees globally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 18, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 4, 2025 | Late filing | Notification of late filing |
| Sep 3, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 23, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 19, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?